The FDA recently approved ublituximab (Briumvi^TM) for the treatment of relapsing forms of Multiple Sclerosis. Ublituximab is a member of the anti-B cell (anti-CD20 monoclonal antibody) family of drugs, which includes rituximab (Rituxan^TM), ocrelizumab (Ocrevus^TM), and ofatumumab (Kesimpta^TM). The primary difference between these drugs is how they are administered and the length of time required to safely administer the medication. Ublituximab, like rituximab and ocrelizumab, is administered intravenously. The initial dose is divided into two doses, given fourteen days apart. Following the starting dose, ublituximab is then administered as a one-hour infusion every six months. There will likely be another several months before various logistical considerations, including insurance coverage, are addressed before ublituximab can actually be provided to patients. Please bring this up with your IMSMP physician at your next office visit if you’d like to learn more.